Your browser doesn't support javascript.
loading
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi, Hayato; Kunimasa, Kei; Kukita, Yoji; Nakamura, Harumi; Honma, Keiichiro; Kawamura, Takahisa; Inoue, Takako; Tamiya, Motohiro; Kuhara, Hanako; Nishino, Kazumi; Mizote, Yu; Akazawa, Takashi; Tahara, Hideaki; Kumagai, Toru.
Afiliação
  • Kawachi H; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Kunimasa K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Kukita Y; Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan.
  • Nakamura H; Laboratory of Genomic Pathology, Osaka International Cancer Institute, Osaka, Japan.
  • Honma K; Department of Diagnostic Pathology & Cytology, Osaka International Cancer Institute, Osaka, Japan.
  • Kawamura T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Inoue T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Tamiya M; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Kuhara H; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Mizote Y; Department of Cancer Drug Discovery & Development, Osaka International Cancer Institute, Osaka, Japan.
  • Akazawa T; Department of Cancer Drug Discovery & Development, Osaka International Cancer Institute, Osaka, Japan.
  • Tahara H; Department of Cancer Drug Discovery & Development, Osaka International Cancer Institute, Osaka, Japan.
  • Kumagai T; Project Division of Cancer Biomolecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Immunotherapy ; 13(10): 799-806, 2021 07.
Article em En | MEDLINE | ID: mdl-34030451
ABSTRACT
SMARCA4-deficient thoracic sarcoma (DTS) is a recently noted progressive thoracic malignancy. We recently experienced three cases of SMARCA4-DTS who were treated with atezolizumab in combination with bevacizumab, paclitaxel and carboplatin (ABCP) as the first-line therapy. Immunohistopathological analysis revealed absent expression of SMARCA4 in all cases. The tumor mutational burden was over 11/Mb and mutations in SMARCA4 and TP53 were detected in all three cases. Partial response to ABCP treatment was observed in all three cases, with a progression-free survival of approximately 6 months or longer and a continuous response of 1 year or longer in one case. The first-line ABCP treatment demonstrated durable efficacy in SMARCA4-DTS regardless of the degree of PD-L1 expression.
Lay abstract Lung cancer is the leading cause of cancer-related death worldwide. Among them, SMARCA4-deficient thoracic sarcoma (DTS), which lacks SMARCA4 expression and exhibits an undifferentiated carcinoma histology, is a recently identified subtype of lung cancer. It tends to occur in younger people with heavy smoking status and has been reported to recur quickly and have a poor prognosis even after chemotherapy, radiation therapy or surgery. There is no effective molecularly targeted agent for SMARCA4-DTS and the identification of an effective therapy is required. Here, we report the clinical features and genomic information of three SMARCA4-DTS cases in which atezolizumab with bevacizumab, paclitaxel and carboplatin treatment was effective. This report suggests the efficacy of atezolizumab with bevacizumab, paclitaxel and carboplatin treatment compared with conventional chemotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma / Fatores de Transcrição / Proteínas Nucleares / Carboplatina / Paclitaxel / DNA Helicases / Anticorpos Monoclonais Humanizados / Bevacizumab / Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma / Fatores de Transcrição / Proteínas Nucleares / Carboplatina / Paclitaxel / DNA Helicases / Anticorpos Monoclonais Humanizados / Bevacizumab / Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article